Is ImmuCell Corporation (ICCC) overvalued? · rev $26.5M
ImmuCell Corporation (ICCC) is a biotechnology company listed on US.
This page asks whether ImmuCell Corporation (ICCC) looks expensive on cached numbers — not a short thesis.
Latest reported ICCC revenue for 2024-12-31 was $26.5M. Net income was -$2.2M. Revenue was up 51.6% from 2023-12-31 to 2024-12-31. ICCC currently screens at market cap $58.9M.
ICCC currently screens at market cap $58.9M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next ICCC 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the ICCC stock page for the full model, not this heading.
Not investment advice.